- 4-Week # shares sold: 36,692
- 12-Week # shares sold: 54,285
- 24-Week # shares sold: 83,649
Jana Partners are placing three members on Tiffany's board.
Biopharma's reticence suggests that fear of Trump's tweets and threats to limit drug pricing (and cut into profits) has stopped biotech companies from standing up for what's right.
Neurocrine Biosciences, Aralez Pharmaceuticals and Qiagen were among the biotech stock movers in premarket trading on Friday.
The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.